NCT02123992

Brief Summary

The aim of this study is to further evaluate the safety and efficacy of the Elevate® Apical and Posterior Prolapse Repair System for repair of apical/posterior pelvic organ prolapse in a controlled, post-market cohort study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Apr 2014

Longer than P75 for phase_4

Geographic Reach
1 country

23 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

April 24, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 28, 2014

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
Last Updated

September 7, 2016

Status Verified

September 1, 2016

Enrollment Period

5 years

First QC Date

April 24, 2014

Last Update Submit

September 6, 2016

Conditions

Outcome Measures

Primary Outcomes (2)

  • Surgical success or failure through composite endpoint including anatomic, subjective and re-treatment measures

    36 months

  • Rate of device or procedure related serious adverse events

    36 months

Secondary Outcomes (3)

  • Surgical success or failure through composite endpoint including anatomic, subjective and re-treatment measures

    36 months

  • Rate of repeat surgery/revision for prolapse arising from the same site/target compartment

    36 months

  • Changes in Quality of Life measured through the following questionaires: PFDI- 20,PFIQ-7, PISQ-12

    36 months

Other Outcomes (3)

  • Subjects experiencing adverse events related to device or procedure

    36 months

  • Subjects experiencing vaginal bulge

    36 months

  • Subjects experiencing prolapse at or beyond the hymenal ring [Time Frame: 36 months

    36 months

Study Arms (2)

Elevate Apical and Posterior

ACTIVE COMPARATOR

The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse

Device: Elevate Apical and Posterior

Native Tissue Repair

ACTIVE COMPARATOR

The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures

Procedure: Native Tissue Repair for pelvic organ prolapse

Interventions

Elevate Apical and Posterior

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is female
  • Subject is at least 18 years of age
  • Subject must have documented diagnosis of posterior or posterior and apical vaginal prolapse with leading edge of pelvic organ prolapse at or beyond the hymen. At or beyond the hymen is defined as POP-Q scores of Bp ≥ 0; or Bp ≥ 0 and C ≥ -1/2 TVL (for a multi-compartment posterior prolapse that includes the apical compartment)
  • Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit")
  • Subject or subject's legally authorized representative is willing to provide written informed consent
  • Subject is willing and able to comply with the follow-up regimen

You may not qualify if:

  • Subject is pregnant or intends to become pregnant during the study
  • Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI) or tissue necrosis
  • Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)
  • Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area
  • Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)
  • Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus erythematosus (SLE), Marfan's syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica)
  • Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis
  • Subject has uncontrolled diabetes mellitus (DM)
  • Subject has a known neurologic or medical condition affecting bladder function (e.g., multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)
  • Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse (colpocleisis)
  • Subject is not able to conform to the modified dorsal lithotomy position
  • Subject is currently participating in or plans to participate in another device or drug study during this study
  • Subject has a known sensitivity to polypropylene
  • Subject has had previous prolapse repair with mesh in the target compartment
  • Subject is planning to undergo a concomitant repair with use of mesh in the non-target compartment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (23)

Urological Associates of Southern Arizona

Tucson, Arizona, 85941, United States

Location

The Clark Center for Urogynecology

Newport Beach, California, 92663, United States

Location

Yale School of Medicine

New Haven, Connecticut, 06520, United States

Location

National Center for Advanced Pelvic Surgery

Washington D.C., District of Columbia, 20010, United States

Location

Women's Health Advantage

Fort Wayne, Indiana, 46825, United States

Location

Metro Urology

Woodbury, Minnesota, 55125, United States

Location

Adult & Pediatric Urology and Urogynecology

Omaha, Nebraska, 68114, United States

Location

Women's Cancer Center of Nevada

Las Vegas, Nevada, 89169, United States

Location

Delaware Valley Urology

Mount Laurel, New Jersey, 08054, United States

Location

Princeton Medical Center

Princeton, New Jersey, 08540, United States

Location

The Center for Specialized Women's Health

Whippany, New Jersey, 07981, United States

Location

North Shore Women's Health Clinic

Great Neck, New York, 11021, United States

Location

Premier Medical Group

Poughkeepsie, New York, 12601, United States

Location

The Institute for Female Pelvic Medicine - St. Luke's Hospital

Allentown, Pennsylvania, 18103, United States

Location

Center for Women's Health of Lansdale

Lansdale, Pennsylvania, 19446, United States

Location

The Female Pelvic Health Center

Newtown, Pennsylvania, 18940, United States

Location

Swan Urogynecology

Nashville, Tennessee, 37203, United States

Location

The Womens Centre

Denton, Texas, 76210, United States

Location

University of Texas at Galveston

Galveston, Texas, 77555, United States

Location

Lone Star Urogynecology and Continence Center

Round Rock, Texas, 78665, United States

Location

Female Pelvic Medicine Institute of Virginia

North Chesterfield, Virginia, 23235, United States

Location

Athena Women's Health

Issaquah, Washington, 98027, United States

Location

University of Washington Pelvic Health Center

Seattle, Washington, 98195, United States

Location

MeSH Terms

Conditions

Pelvic Organ Prolapse

Condition Hierarchy (Ancestors)

ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Eric R Sokol, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2014

First Posted

April 28, 2014

Study Start

April 1, 2014

Primary Completion

April 1, 2019

Study Completion

April 1, 2019

Last Updated

September 7, 2016

Record last verified: 2016-09

Data Sharing

IPD Sharing
Will share

Data will be shared at a later data by the American Urogynecology Society aggregated with other data extracted from a national registry database.

Locations